A recent study conducted in the UK showed that breast cancer women without previous CV diseases treated with aromatase inhibitors had higher risk of heart failure (HR = 2.80, 1.29 to 6.08) than those treated with tamoxifen. Here, CYP19A1 is linked to breast cancer.